Research team discovers unexpected source of diabetic neuropathy pain

17 May 2012

1
Nearly half of all diabetics suffer from neuropathic pain, an intractable, agonizing and still mysterious companion of the disease. Now Yale researchers have identified an unexpected source of the pain and a potential target to alleviate it.
 
A team of researchers from Yale and the West Haven Veterans Affairs Medical Center describes in the 15 May issue of the Journal of Neuroscience how changes in the structure of dendritic spines – microscopic projections on the receiving branches of nerve cells - are associated with pain in laboratory rats with diabetes.
 
''How diabetes leads to neuropathic pain is still a mystery,'' said Andrew Tan, an associate research scientist in neurology at the Yale School of Medicine and lead author of the study. ''An interesting line of study is based on the idea that neuropathic pain is due to faulty 'rewiring' of pain circuitry.''
 
With a growing number of diabetics, the condition represents a huge unmet medical need. Once neuropathic pain is established, it is a lifelong condition.
 
''Here we reveal that these dendritic spines, first studied in memory circuit processing, also contribute to the sensation of pain in diabetes,'' Tan said. A single neuron may contain hundreds to thousands of dendritic spines.
 
The Yale team led by Tan and senior author Dr. Stephen G. Waxman, the Bridget Marie Flaherty Professor of Neurology, professor of neurobiology and pharmacology, found abnormal dendritic spines were associated with the onset and maintenance of pain. They also found that a drug that interferes with formation of these spines reduced pain in lab animals, suggesting that targeting abnormal spines could be a therapeutic strategy.
 
Tan said that these dendritic spines in nerve cells seem to store memory of pain, just as they are crucial in memory and learning in the human brain.
 
''We have identified a single, key molecule that controls structural changes in these spines and hopefully we can develop therapeutic approaches that target that molecule and  reduce diabetic pain,'' Waxman said.

Latest articles

OpenClaw founder Peter Steinberger joins OpenAI as personal-agent project moves to foundation

OpenClaw founder Peter Steinberger joins OpenAI as personal-agent project moves to foundation

Fractal Analytics shares slip on debut as AI uncertainty weighs on sentiment

Fractal Analytics shares slip on debut as AI uncertainty weighs on sentiment

Warner Bros weighs reopening sale talks with Paramount amid competing bids

Warner Bros weighs reopening sale talks with Paramount amid competing bids

ByteDance pledges safeguards for Seedance AI after studios raise IP concerns

ByteDance pledges safeguards for Seedance AI after studios raise IP concerns

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China

Musk ramps up SpaceX moon plans as Bezos accelerates Blue Origin in race against China

Indians can now travel to 56 destinations without prior visa as passport ranking improves

Indians can now travel to 56 destinations without prior visa as passport ranking improves

CEO says EU’s IRIS2 must match Starlink on price and performance

CEO says EU’s IRIS2 must match Starlink on price and performance

Applied Materials jumps 12% as AI chip demand drives strong revenue forecast

Applied Materials jumps 12% as AI chip demand drives strong revenue forecast

Opening the silos: India approves 3 million tonnes of wheat and product exports

Opening the silos: India approves 3 million tonnes of wheat and product exports